Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP7 | P09237 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3097616 | 1.00 | KCNA5 (0.38) | KCNA5NAMPTPOLBKMT2APKM | |
| SCHEMBL3103817 | 0.89 | KMT2A (0.42) | POLBKMT2APKMHTTNOS3 | |
| SCHEMBL3103813 | 0.89 | KMT2A (0.42) | POLBKMT2APKMHTTNOS3 | |
| Hydrochloric Acid SCHEMBL3088702 | 0.85 | HTT (0.39) | POLBHTTPTGS2LMNAMMP1 | |
| Hydrochloric Acid SCHEMBL3088705 | 0.85 | HTT (0.39) | POLBHTTPTGS2LMNAMMP1 | |
| SCHEMBL3093148 | 0.84 | HTT (0.39) | POLBKMT2AHTTPTGS2MEN1 | |
| SCHEMBL3093158 | 0.84 | HTT (0.39) | POLBKMT2AHTTPTGS2MEN1 | |
| SCHEMBL3091863 | 0.83 | NR1H4 (0.40) | POLBKMT2APKMHTTLMNA | |
| SCHEMBL3091874 | 0.83 | NR1H4 (0.40) | POLBKMT2APKMHTTLMNA | |
| SCHEMBL3078553 | 0.83 | CNR1 (0.41) | POLBKMT2APKMHTTNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180280326-A1 | MEDICAMENT FOR PREVENTING OR INHIBITING ACUTE KIDNEY INJURY | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2018-10-04 | — | — | US | claimed |
| US-10071099-B2 | Medicament for suppressing malignant tumor metastasis | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2018-09-11 | — | — | US | claimed |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | claimed |
| EP-2172450-B9 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-08 | — | — | EP | claimed |
| EP-2172450-B1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-16 | — | — | EP | claimed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | claimed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | claimed |
| EP-2172450-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-07 | — | — | EP | claimed |
| US-20180280326-A1 | MEDICAMENT FOR PREVENTING OR INHIBITING ACUTE KIDNEY INJURY | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2018-10-04 | — | — | US | disclosed |
| US-10071099-B2 | Medicament for suppressing malignant tumor metastasis | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2018-09-11 | — | — | US | disclosed |
| EP-2172450-B9 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-2172450-B1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2172450-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280326-A1 | MEDICAMENT FOR PREVENTING OR INHIBITING ACUTE KIDNEY INJURY | AGTR2, AGTR1, REN | KCNA5 2260/4885NAMPT 2010/4885POLB 4639/4885 |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | KCNA5 339/4885NAMPT 2385/4885POLB 4626/4885 |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | AGTR2, MME, AGTR1 | KCNA5 2253/4885NAMPT 1064/4885POLB 4812/4885 |
| US-10071099-B2 | Medicament for suppressing malignant tumor metastasis | AGTR2, MME, AGTR1 | KCNA5 2253/4885NAMPT 1064/4885POLB 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.